vs

Side-by-side financial comparison of Fossil Group, Inc. (FOSL) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.

Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $270.2M, roughly 1.8× Fossil Group, Inc.). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs -14.8%, a 21.6% gap on every dollar of revenue. On growth, Pediatrix Medical Group, Inc. posted the faster year-over-year revenue change (-1.7% vs -21.1%). Over the past eight quarters, Pediatrix Medical Group, Inc.'s revenue compounded faster (-0.1% CAGR vs -11.4%).

Fossil Group, Inc., is an American fashion design and manufacturer founded in 1984 by Tom Kartsotis and based in Richardson, Texas. Their brands include Fossil, Relic, Michele Watch, Skagen Denmark, WSI, and Zodiac Watches. Fossil also makes licensed accessories for brands such as BMW, Puma, Emporio Armani, Michael Kors, DKNY, Diesel, Kate Spade New York, Tory Burch, Chaps, and Armani Exchange.

Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.

FOSL vs MD — Head-to-Head

Bigger by revenue
MD
MD
1.8× larger
MD
$493.8M
$270.2M
FOSL
Growing faster (revenue YoY)
MD
MD
+19.4% gap
MD
-1.7%
-21.1%
FOSL
Higher net margin
MD
MD
21.6% more per $
MD
6.8%
-14.8%
FOSL
Faster 2-yr revenue CAGR
MD
MD
Annualised
MD
-0.1%
-11.4%
FOSL

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
FOSL
FOSL
MD
MD
Revenue
$270.2M
$493.8M
Net Profit
$-40.0M
$33.7M
Gross Margin
49.0%
Operating Margin
-8.0%
9.9%
Net Margin
-14.8%
6.8%
Revenue YoY
-21.1%
-1.7%
Net Profit YoY
-257.8%
10.5%
EPS (diluted)
$-0.76
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FOSL
FOSL
MD
MD
Q4 25
$270.2M
$493.8M
Q3 25
$220.4M
$492.9M
Q2 25
$233.3M
$468.8M
Q1 25
$458.4M
Q4 24
$342.3M
$502.4M
Q3 24
$287.8M
$511.2M
Q2 24
$260.0M
$504.3M
Q1 24
$254.9M
$495.1M
Net Profit
FOSL
FOSL
MD
MD
Q4 25
$-40.0M
$33.7M
Q3 25
$-2.1M
$71.7M
Q2 25
$-17.9M
$39.3M
Q1 25
$20.7M
Q4 24
$-11.2M
$30.5M
Q3 24
$-31.9M
$19.4M
Q2 24
$-38.8M
$-153.0M
Q1 24
$-24.3M
$4.0M
Gross Margin
FOSL
FOSL
MD
MD
Q4 25
49.0%
Q3 25
57.5%
Q2 25
61.3%
Q1 25
Q4 24
53.9%
Q3 24
49.4%
Q2 24
52.6%
Q1 24
52.4%
Operating Margin
FOSL
FOSL
MD
MD
Q4 25
-8.0%
9.9%
Q3 25
3.9%
13.8%
Q2 25
-2.9%
12.8%
Q1 25
7.0%
Q4 24
-4.8%
7.8%
Q3 24
-8.5%
6.6%
Q2 24
-13.1%
-31.3%
Q1 24
-11.5%
3.2%
Net Margin
FOSL
FOSL
MD
MD
Q4 25
-14.8%
6.8%
Q3 25
-1.0%
14.5%
Q2 25
-7.7%
8.4%
Q1 25
4.5%
Q4 24
-3.3%
6.1%
Q3 24
-11.1%
3.8%
Q2 24
-14.9%
-30.3%
Q1 24
-9.5%
0.8%
EPS (diluted)
FOSL
FOSL
MD
MD
Q4 25
$-0.76
$0.40
Q3 25
$-0.04
$0.84
Q2 25
$-0.33
$0.46
Q1 25
$0.24
Q4 24
$-0.15
$0.37
Q3 24
$-0.60
$0.23
Q2 24
$-0.73
$-1.84
Q1 24
$-0.46
$0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FOSL
FOSL
MD
MD
Cash + ST InvestmentsLiquidity on hand
$79.2M
$375.2M
Total DebtLower is stronger
$169.1M
$570.5M
Stockholders' EquityBook value
$112.6M
$865.9M
Total Assets
$701.0M
$2.2B
Debt / EquityLower = less leverage
1.50×
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FOSL
FOSL
MD
MD
Q4 25
$79.2M
$375.2M
Q3 25
$109.9M
$340.1M
Q2 25
$78.3M
$224.7M
Q1 25
$99.0M
Q4 24
$123.6M
$229.9M
Q3 24
$106.3M
$103.8M
Q2 24
$104.9M
$19.4M
Q1 24
$112.9M
$8.0M
Total Debt
FOSL
FOSL
MD
MD
Q4 25
$169.1M
$570.5M
Q3 25
$165.6M
$577.2M
Q2 25
$167.2M
$583.9M
Q1 25
$590.5M
Q4 24
$162.7M
$597.1M
Q3 24
$173.4M
Q2 24
$156.5M
Q1 24
$202.9M
Stockholders' Equity
FOSL
FOSL
MD
MD
Q4 25
$112.6M
$865.9M
Q3 25
$150.3M
$890.7M
Q2 25
$140.6M
$833.8M
Q1 25
$789.2M
Q4 24
$148.7M
$764.9M
Q3 24
$164.4M
$732.5M
Q2 24
$189.6M
$706.5M
Q1 24
$229.1M
$856.2M
Total Assets
FOSL
FOSL
MD
MD
Q4 25
$701.0M
$2.2B
Q3 25
$704.5M
$2.2B
Q2 25
$686.0M
$2.1B
Q1 25
$2.0B
Q4 24
$763.6M
$2.2B
Q3 24
$812.4M
$2.1B
Q2 24
$785.7M
$2.0B
Q1 24
$891.0M
$2.2B
Debt / Equity
FOSL
FOSL
MD
MD
Q4 25
1.50×
0.66×
Q3 25
1.10×
0.65×
Q2 25
1.19×
0.70×
Q1 25
0.75×
Q4 24
1.09×
0.78×
Q3 24
1.06×
Q2 24
0.83×
Q1 24
0.89×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FOSL
FOSL
MD
MD
Operating Cash FlowLast quarter
$-22.2M
$114.1M
Free Cash FlowOCF − Capex
$-22.5M
FCF MarginFCF / Revenue
-8.3%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
3.39×
TTM Free Cash FlowTrailing 4 quarters
$-46.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FOSL
FOSL
MD
MD
Q4 25
$-22.2M
$114.1M
Q3 25
$9.4M
$137.3M
Q2 25
$-60.4M
$137.2M
Q1 25
$-117.5M
Q4 24
$30.5M
$133.0M
Q3 24
$-22.8M
$91.8M
Q2 24
$38.4M
$107.0M
Q1 24
$622.0K
$-125.2M
Free Cash Flow
FOSL
FOSL
MD
MD
Q4 25
$-22.5M
Q3 25
$8.6M
Q2 25
$-60.6M
Q1 25
Q4 24
$28.5M
Q3 24
$-24.1M
Q2 24
$36.6M
Q1 24
$-1.1M
FCF Margin
FOSL
FOSL
MD
MD
Q4 25
-8.3%
Q3 25
3.9%
Q2 25
-26.0%
Q1 25
Q4 24
8.3%
Q3 24
-8.4%
Q2 24
14.1%
Q1 24
-0.4%
Capex Intensity
FOSL
FOSL
MD
MD
Q4 25
0.1%
Q3 25
0.4%
Q2 25
0.1%
Q1 25
Q4 24
0.6%
Q3 24
0.4%
Q2 24
0.7%
Q1 24
0.7%
Cash Conversion
FOSL
FOSL
MD
MD
Q4 25
3.39×
Q3 25
1.91×
Q2 25
3.49×
Q1 25
-5.66×
Q4 24
4.36×
Q3 24
4.72×
Q2 24
Q1 24
-31.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FOSL
FOSL

Transferred At Point In Time$109.7M41%
Traditional Watches$91.3M34%
Other$50.8M19%
Leathers$9.5M4%
Jewelry$4.0M1%
Smartwatches$3.3M1%
Products Other$1.6M1%

MD
MD

Health Care Patient Service$421.6M85%
Hospitals Contracts$70.0M14%
Other$2.2M0%

Related Comparisons